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Background: Randomized controlled trials indicate that patent foramen ovale (PFO)
closure reduces risk of stroke recurrence in patients with cryptogenic stroke and PFO.
However, the optimal time point for PFO closure is unknown and depends on the risk of
stroke recurrence.
Objective: We aimed to investigate risk of early new ischemic lesions on cerebral
magnetic resonance imaging (MRI) in cryptogenic stroke patients with and without PFO.
Methods: Cryptogenic stroke patients underwent serial MRI examinations within 1
week after symptom onset to detect early new ischemic lesions. Diffusion-weighted
imaging (DWI) lesions were delineated, co-registered, and analyzed visually for new
hyperintensities by raters blinded to clinical details. A PFOwas classified as stroke-related
in patients with PFO and a Risk of Paradoxical Embolism (RoPE) score >5 points.
Results: Out of 80 cryptogenic stroke patients, risk of early recurrent DWI lesions was
not significantly different in cryptogenic stroke patients with and without PFO. Similar
results were observed in patients ≤60 years of age. Patients with a stroke-related PFO
even had a significantly lower risk of early recurrent ischemic lesions compared to all other
patients with cryptogenic stroke (unadjusted odds ratio 0.23 [95% confidence interval
0.06–0.87], P = 0.030).
Conclusion: Our data argue against a high risk of early stroke recurrence in patients
with cryptogenic stroke and PFO.
Keywords: patent foramen ovale, stroke, MRI–magnetic resonance imaging, diffusion-weighted (DW) imaging,
new ischemic lesions
INTRODUCTION
In the general population, prevalence of patent foramen ovale (PFO) is ∼25% (1). Prevalence of
PFO in patients with cryptogenic stroke is significantly higher than in the general population (2–5).
In these patients, PFO is considered a possible etiology of stroke. The suggested pathophysiologic
mechanisms include paradoxical embolism and local intraseptal thrombosis (5–9).
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Randomized controlled trials indicate that patent foramen
ovale (PFO) closure combined with antiplatelet therapy
compared to antiplatelet therapy alone significantly reduces risk
of stroke recurrence in young patients with cryptogenic stroke
and PFO (10–12). Evidence in favor of PFO closure raises the
question whether PFO closure is an urgent matter (13). However,
the optimal time point for PFO closure is unknown and depends
on the risk of stroke recurrence (14). New diffusion-weighted
imaging (DWI) lesions after acute ischemic stroke are a sensitive
marker for new ischemic events and are detected more frequently
than clinical stroke recurrence alone (15–20). Here we analyzed,
whether presence of PFO in cryptogenic stroke patients is
associated with occurrence of early recurrent DWI lesions within
1 week after stroke.
MATERIALS AND METHODS
Study Design and Patients
We performed a post-hoc analysis of data drawn from an
observational study conducted by the Center for Stroke Research
Berlin (CSB) at the Charité—Universitätsmedizin Berlin,
Campus Benjamin Franklin (Berlin, Germany; clinicaltrials.gov:
NCT00715533). The study included acute ischemic stroke
patients that were able to undergo MRI within 24 h after
symptom onset (16–18, 21). We included patients recruited
between March, 2008 and December, 2010 with a complete
set of three MRI examinations within the first week after
symptom onset and an undetermined etiology of stroke
according to Trial of Org 10172 in Acute Stroke Treatment
(TOAST) criteria (22). Diagnostic work-up in all patients
included MRI, MR-angiography, carotid ultrasonography and
cardiac rhythm monitoring for at least 24 h. Patients with
multiple potential causes of stroke (22) and patients who
underwent endovascular revascularization procedures were
excluded. We excluded patients who underwent endovascular
revascularization procedures, because endovascular procedures
may cause new DWI lesions on MRI (23, 24). Patients who
received thrombolysis were not excluded. All patients included
in this study received standard stroke unit care following the
guidelines of the European Stroke Organization (ESO) and
the German Stroke Society (DSG; https://www.dsg-info.de/
stroke-units/stroke-units-uebersicht.html). None of the patients
included in this study underwent PFO closure during the study
period. The study was approved by the local Ethics Committee
(EA4/026/08). All patients gave written informed consent.
MRI
Details have been reported previously (18, 21). In short,
we conducted three cerebral MRI examinations on a 3-
Tesla MRI scanner (Tim Trio, Siemens Medical, Erlangen,
Germany): on admission, on the following day, and 4 to 7
days after symptom onset. DWI images were pseudonymized
and afterwards reviewed in random order. Raters were blinded
to clinical information. Hyperintensities on initial DWIs were
delineated manually and then co-registered. Co-registered DWIs
were analyzed visually for new hyperintensities through slice-by-
slice comparison of the first and second, as well as the second and
third DWI. New hyperintensities had to be clearly separate from
the index lesion. All new diffusion hyperintensities regardless of
apparent diffusion coefficient value were considered (17, 18, 21)
Number of new DWI lesions was counted.
Clinical Data
Sociodemographic and laboratory data were collected from the
medical records. All patients were assessed for stroke severity
directly before the first MRI examination by physicians certified
to assess the National Institutes of Health Stroke Scale (NIHSS)
(25). PFO was diagnosed by transesophageal echocardiography
(TEE) or transcranial Doppler. Both techniques have similar
sensitivity and specificity (5, 26, 27). An associated atrial septum
aneurysm (ASA) was diagnosed in patients with septum primum
excursion >10mm on TEE (11). The Risk of Paradoxical
Embolism (RoPE) score was used to differentiate between
patients with a high probability of a stroke-related PFO (high
attributable risk) vs. an incidental PFO.(26, 28) The RoPE score
is externally validated (28, 29) and varies from 0 to 9 points
with higher scores indicating a higher attributable risk. In stroke
patients with PFO and a RoPE score >5 points, the PFO has
an attributable risk for stroke of 62% or more (28). Therefore
in this study, patients with an undetermined etiology of stroke
(22), PFO and a RoPE score >5 points were assumed to have a
stroke-related PFO.
Statistics
For comparisons of nominal and categorical variables, we
used unadjusted, univariate logistic regression to obtain odds
ratios (OR) and corresponding 95% confidence intervals (CI).
Additionally, we used chi-square test to compare (1) patients with
and without data available regarding PFO and (2) patients with
and without tested PFO parameters (any PFO, stroke-related
PFO, PFO in patients ≤60 years of age) regarding appearance
of new DWI lesions. For comparisons of continuous variables,
we used the Mann–Whitney U-test. Statistical significance was
determined at an alpha level of 0.05 (16–18, 21).
RESULTS
Out of 340 acute ischemic stroke patients examined, 98 patients
(29%) had a cryptogenic stroke defined as stroke of undetermined
etiology. Of these, 80 patients had data available regarding
PFO and constitute the study population (Figure 1, Table 1).
Cryptogenic stroke patients with and without data available
regarding PFO did not differ regarding sex and NIHSS > 3
points. Patients without data available regarding PFO were more
often > 60 years of age (88.9 vs. 57.5%, p= 0.013).
Thirty-two out of 80 patients (40%) had any PFO and 18/80
patients (23%) with PFO had a RoPE score >5 points (stroke-
related PFO). Early recurrent DWI lesions were detected in 11
of 32 patients (34%) with any PFO and in 3 of 18 patients (17%)
with a stroke-related PFO.
Neither any PFO (unadjusted OR 0.67 [95%CI 0.27–1.70], p
= 0.403; 34% [with PFO] vs. 44% [without PFO], p = 0.402)
nor stroke-related PFO were significantly positively associated
with early recurrent DWI lesions. On the contrary, stroke-related
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FIGURE 1 | Data flow diagram.
PFO was negatively associated with early recurrent DWI lesions
(unadjusted OR 0.23 [95%CI 0.06–0.87], p = 0.030; 17% [with
stroke-related PFO] vs. 47% [without PFO or with incidental
PFO], p = 0.022). Factors associated with early recurrent DWI
lesions were diabetes mellitus, arterial hypertension, and older
age (Table 2).
Out of the 80 patients with cryptogenic stroke, 34 patients
were ≤60 years of age (29% women; median age [years]: 48
[interquartile range {IQR}, 41–52]; median NIHSS: 2 [IQR, 1–
4]). Of these, 20 patients (59%) had a PFO (18/20 patients had a
stroke-related PFO). Early recurrent DWI lesions were detected
in 3 of 20 patients (15%) with PFO. PFO was not positively
associated with early recurrent DWI lesions [unadjusted OR 0.44
[95%CI 0.08–2.39], p = 0.342; 15% [with PFO] vs. 29% [without
PFO], p= 0.335].
Results did not change when PFO and an associated atrial
septal aneurysm (ASA) was taken into account (PFO+ASA:
unadjusted OR 0.51 [95%CI 0.12–2.09], p = 0.349; PFO+ASA
in patients ≤60 years of age: unadjusted OR 0.54 [95%CI 0.05 –
5.50], p= 0.605).
The number of early recurrent DWI lesions was significantly
lower in cryptogenic stroke patients with any PFO (32/80)
compared to patients without PFO (median: 2 [IQR, 1-2] vs. 5
[IQR, 2–8]; p= 0.014).
DISCUSSION
In this population of patients with cryptogenic stroke undergoing
serial MRI examinations, PFO was not associated with early
recurrent ischemic lesions.
Risk of stroke recurrence may vary over time. For
example, in stroke patients with symptomatic carotid stenosis,
TABLE 1 | Sociodemographic and clinical characteristics of the study population.
Characteristic
Sex (female), n (%) 29 (36%)
Age (years), median (IQR) 65 (49–72)
NIHSS, median (IQR) 2.5 (1–5)
Diabetes mellitus, n (%) 11 (14%)
Arterial hypertension, n (%) 46 (58%)
CHD, n (%) 5 (6%)
Previous stroke, n (%) 16 (20%)
Prior antiplatelet therapy, n (%) 16 (20%)
Thrombolysis, n (%) 18 (23%)
Antiplatelet therapy during hospital stay, n (%) a 73 (91%)
Anticoagulation during hospital stay, n (%) b 4 (5%)
Any PFO, n (%) 32 (40%)
PFO + ASA, n (%) c 11 (14%)
PFO + RoPE score > 5 points, n (%) 18 (23%)
NIHSS indicates National Institutes of Health Stroke Scale; CHD, coronary heart disease;
PFO, patent foramen ovale; and ASA, atrial septal aneurysm.
aThe variable antiplatelet therapy during hospital stay was known in 77/80 patients. bThe
variable anticoagulation during hospital stay was known in 77/80 patients. cThe variable
PFO + ASA was known in 77/80 patients.
endarterectomy should be done within the first 2 weeks after
the initial event because the survival curve for recurrence is
front-loaded (30, 31).
In general stroke cohorts, early recurrent ischemic lesions
are reported to appear in 24–34% of patients while higher rates
are reported, for example, in acute stroke patients with large
artery atherosclerosis (20). In this study, frequency of early
recurrent ischemic lesions was lower both in patients with a
stroke-related PFO (17%) and in young stroke patients≤60 years
of age with PFO (15%). In all tested conditions (any PFO, stroke-
related PFO, PFO in patients ≤60 years of age) presence of
PFO was not positively associated with early recurrent ischemic
lesions. In the CLOSE trial (Patent Foramen Ovale Closure
or Anticoagulants vs. Antiplatelet Therapy to Prevent Stroke
Recurrence) (11) only stroke patients with PFO and additional
echocardiographic features like ASA were included. Therefore,
we included PFO and an associated ASA as an additional
parameter but lack of association regarding early recurrent
ischemic lesions remained. Patients with a stroke-related PFO
even had a significantly lower risk of early recurrent ischemic
lesions compared to all other patients with cryptogenic stroke
(patients without PFO and patients with an incidental PFO)–
this result complements a previous study that reported a low
long-term risk of a clinically diagnosed stroke recurrence in
patients with a stroke-related PFO (28). In addition, number
of early recurrent ischemic lesions in patients with any PFO
was significantly lower compared to patients without PFO. In
contrast to PFO, well-known risk factors for both clinically
overt and silent stroke recurrence like diabetes mellitus, arterial
hypertension, and older age (32, 33) were associated with
an increased risk of early recurrent ischemic lesions in this
cohort.
Limitations of this study have to be considered. First, this is a
single-center post-hoc analysis. Second, the number of patients
was small. We cannot exclude a type-2 error with respect to
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TABLE 2 | Sociodemographic and clinical characteristics of the study population




Sex (female) 0.87 (0.34 – 2.22) 0.776
Age > 60 years 4.59 (1.67 – 12.65) 0.003
NIHSS > 3 points 0.96 (0.39 – 2.38) 0.926
Diabetes mellitus 5.00 (1.21 – 20.61) 0.026
Arterial hypertension 3.55 (1.33 – 9.46) 0.011
CHD 1.00 (0.16 – 6.35) 1.000
Previous stroke 2.29 (0.75 – 6.97) 0.144
Thrombolysis 1.70 (0.59 – 4.88) 0.328
Glucose > 10 mmol/l a 2.35 (0.49 – 11.34) 0.289
LDL > 3.4 mmol/l b 1.17 (0.45 – 3.03) 0.752
Antiplatelet therapy during hospital stay c 0.70 (0.09 – 5.23) 0.726
Anticoagulation during hospital stay d 1.43 (0.19 – 10.75) 0.726
Any PFO 0.67 (0.27 – 1.70) 0.403
PFO + RoPE score > 5 points 0.23 (0.06 – 0.87) 0.030
Any PFO in patients ≤60 years of age e 0.44 (0.08 – 2.39) 0.342
NIHSS indicates National Institutes of Health Stroke Scale; CHD, coronary heart disease;
LDL, low-density lipoprotein; PFO, patent foramen ovale; and RoPE, Risk of Paradoxical
Embolism score.
aThe variable glucose was known in 76/80 patients. bThe variable LDL was known in
74/80 patients. cThe variable antiplatelet therapy during hospital stay was known in 77/80
patients. dThe variable anticoagulation during hospital stay was known in 77/80 patients.
eThe variable any PFO in patients≤60 years of age was known in 34 patients. Bold values
are statistically significant results.
non-significant findings. Still, the point estimates argue against
a clinically relevant, increased risk of early recurrent ischemic
lesions in patients with PFO. Patients with a stroke-related PFO
had a significantly lower risk of early recurrent ischemic lesions.
In addition, the number of early recurrent ischemic lesions in
patients with any PFO was significantly lower.
In conclusion, our data argue against a high risk of early
stroke recurrence in patients with cryptogenic stroke and PFO,
especially in patients eligible for PFO closure (≤60 years of
age, patients with PFO and an associated ASA). Therefore, our
findings suggest that PFO closure does not necessarily have to be
performed early after the initial stroke. Rather a comprehensive
clinical assessment to exclude other potential causes of stroke
should be prioritized.
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